Medication info
Yugenta Duo Tablet 2.5/1000 mg

Yugenta Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Youyoung Pharmaceutical Co., Ltd.
Appearance
Bright pink, double convex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging x 6)
Approval status
Active

MFDS item code 201803844 · Approved 2018.09.28

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for the following patients in Precautions for Use). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for the following patients in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in Precautions for Use).

Ingredients

Manufacturer
Youyoung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This drug is used to improve blood sugar control in adult patients with type 2 diabetes. It is administered to patients who are receiving diabetes medication for the first time or have difficulty controlling blood sugar with monotherapy. Additionally, this drug can be used when blood sugar control is insufficient with metformin monotherapy. It is also effective in replacing the combination therapy of linagliptin and metformin. When blood sugar control is challenging with the maximum doses of metformin combined with sulfonylureas or insulin and metformin combination therapy, this drug can be used in combination to provide assistance. Finally, this drug can be added to combinations with metformin and empagliflozin to enhance treatment efficacy when blood sugar control is inadequate. Thus, this drug is used to complement various treatment methods to improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for the following patients in Precautions for Use). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for the following patients in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in Precautions for Use).

Precautions

This drug can cause a rare complication known as lactic acidosis, which is particularly dangerous for patients with impaired renal function or severe heart disease. This drug should not be used if there is an allergy to any ingredient, or if the patient has type 1 diabetes, diabetic ketoacidosis, severe renal impairment, liver dysfunction, acute alcohol intoxication, or certain other diseases. Caution is necessary when used with other blood sugar-lowering medications due to the risk of hypoglycemia, especially when combined with insulin or sulfonylureas, where dose adjustments may be necessary. Patients with reduced kidney function should undergo regular kidney function tests before and during treatment with this drug. Caution is advised in patients with heart disease, such as heart failure or acute myocardial infarction. If an iodine contrast agent is used during radiological examinations, this drug should be discontinued for a certain period before and after the test and can be resumed only after stabilizing kidney function. Acute pancreatitis or blistering skin diseases may occur; if severe abdominal pain or skin abnormalities appear during treatment, consult a physician immediately. This drug can lower vitamin B12 levels; therefore, checking for vitamin B12 deficiency may be necessary during prolonged use. Women who are pregnant or may become pregnant, as well as breastfeeding mothers, are advised not to use this drug and should consult with a physician if planning to become pregnant. The safety in children under 10 years old and teenagers has not been established, and usage is not recommended. Elderly patients may experience reduced kidney function; therefore, regular monitoring of kidney function and starting at the minimum dose is important. In case of overdose, serious adverse effects such as lactic acidosis may occur, requiring immediate medical treatment. This drug should be stored away from moisture and direct sunlight, and kept out of reach of children, and it is advisable not to transfer it into another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced vitamin B12 and deficiency
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 141 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • death
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • colorectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • erectile dysfunction
  • goiter
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • skeletal contusion
  • concussion
  • bone fracture
  • hand fracture
  • drowsiness
  • palpitations
  • dry eyes
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • benign prostatic hyperplasia
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the drug's efficacy over time.

Appearance and packaging

Appearance

Bright pink, double convex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.